Literature DB >> 26048514

Detailed characterization of incretin cell distribution along the human small intestine.

Tiago P Guedes1, Sofia Martins1, Madalena Costa1, Sofia S Pereira1, Tiago Morais1, Agostinho Santos2, Mário Nora3, Mariana P Monteiro4.   

Abstract

BACKGROUND: Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), are physiologic stimulants of insulin release that have been implicated in diabetes remission after bariatric surgery. The detailed distribution of incretin cells along the human small gut, so far unknown, is of utmost importance for the understanding of the metabolic changes observed after bariatric surgery because diabetes remission rate varies according to the type of anatomic rearrangement.
OBJECTIVE: To characterize the distribution of incretin producing cells along the human jejunum-ileum.
SETTING: Academic public institution.
METHODS: Small intestines (n = 30) from autopsies were sampled every 20 cm along their entire length and tissue microarrays were constructed. The percentage of immunohistochemistry-stained cell areas for GLP-1, GIP, and chromogranin A at each segment length was quantified using a computer-aided analysis tool.
RESULTS: The percentage of stained area for GLP-1 immunoreactive cells was found to be significantly higher from 200 cm from Treitz ligament onward compared with the first 80 cm of the small intestine, whereas GIP immunoreactive cells were predominant expressed in the first 80 cm. In contrast, chromogranin A expression was constant along the entire jejunum-ileum.
CONCLUSION: The uneven distribution of GLP-1-expressing cells, with a higher density from 200 cm of the jejunum-ileum, could contribute to explain the improvement of glycemic profile of diabetic patients observed after anatomic rearrangement of the intestinal tract, in particular when subjected to gastric bypass with longer biliopancreatic limbs.
Copyright © 2015 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Human; Incretins; K cells; L cells; Small intestine

Mesh:

Substances:

Year:  2015        PMID: 26048514     DOI: 10.1016/j.soard.2015.02.011

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  14 in total

1.  Enteroendocrine K and L cells in healthy and type 2 diabetic individuals.

Authors:  Tina Jorsal; Nicolai A Rhee; Jens Pedersen; Camilla D Wahlgren; Brynjulf Mortensen; Sara L Jepsen; Jacob Jelsing; Louise S Dalbøge; Peter Vilmann; Hazem Hassan; Jakob W Hendel; Steen S Poulsen; Jens J Holst; Tina Vilsbøll; Filip K Knop
Journal:  Diabetologia       Date:  2017-09-28       Impact factor: 10.122

2.  Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication.

Authors:  Anna Casajoana; Jordi Pujol; Amador Garcia; Jordi Elvira; Nuria Virgili; Francisco Javier de Oca; Xavier Duran; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

3.  Metabolic Surgery Comparing Sleeve Gastrectomy with Jejunal Bypass and Roux-en-Y Gastric Bypass in Type 2 Diabetic Patients After 3 Years.

Authors:  Matías Sepúlveda; Munir Alamo; Yudith Preiss; Juan P Valderas
Journal:  Obes Surg       Date:  2018-11       Impact factor: 4.129

4.  Immunohistochemical Staining for Uroguanylin, a Satiety Hormone, is Decreased in Intestinal Tissue Specimens From Female Adolescents With Obesity.

Authors:  Matthew D Di Guglielmo; Lacey Perdue; Adebowale Adeyemi; Kenneth L van Golen; Diana U Corao
Journal:  Pediatr Dev Pathol       Date:  2017-08-29

5.  A Prospective Single-Arm Trial of Modified Long Biliopancreatic and Short Alimentary Limbs Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity.

Authors:  Abdon José Murad; Ricardo Vitor Cohen; Eudes Paiva de Godoy; Christian Lamar Scheibe; Giuliano Peixoto Campelo; Almino Cardoso Ramos; Roclides Castro de Lima; Luís Eduardo Veras Pinto; Daniel Coelho; Hamilton Belo França Costa; Ígor Marreiros Pereira Pinto; Tiago Pereira; Francisco Raúl Santos Teófilo; José Aparecido Valadão
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

6.  Role of Gastrointestinal Hormones as a Predictive Factor for Long-Term Diabetes Remission: Randomized Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy, and Greater Curvature Plication.

Authors:  Anna Casajoana; Fernando Guerrero-Pérez; Amador García Ruiz de Gordejuela; Víctor Admella; Maria Sorribas; Anna Vidal-Alabró; Núria Virgili; Rafael López Urdiales; Mónica Montserrat; Manuel Pérez-Maraver; Carme Monasterio; Neus Salord; Silvia Pellitero; Sonia Fernández-Veledo; Joan Vendrell; Jordi Pujol Gebelli; Núria Vilarrasa
Journal:  Obes Surg       Date:  2021-01-05       Impact factor: 4.129

7.  IMMUNOHISTOCHEMICAL DETECTION OF L CELLS IN GASTROINTESTINAL TRACT MUCOSA OF PATIENTS AFTER SURGICAL TREATMENT FOR CONTROL OF TYPE 2 DIABETES MELLITUS.

Authors:  Priscila Costa Estabile; Mara Cristina de Almeida; Eduardo Bauml Campagnoli; Marco Aurelio Santo; Marcos Ricardo da Silva Rodrigues; Fábio Quirillo Milléo; Roberto Ferreira Artoni
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

8.  A Matched Cohort Analysis of Sleeve Gastrectomy With and Without 300 cm Loop Duodenal Switch With 18-Month Follow-Up.

Authors:  Austin Cottam; Daniel Cottam; Mitchell Roslin; Samuel Cottam; Walter Medlin; Christina Richards; Amit Surve; Hinali Zaveri
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

9.  Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes?

Authors:  Mário Nora; Tiago Morais; Rui Almeida; Marta Guimarães; Mariana P Monteiro
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 10.  What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?

Authors:  Rune E Kuhre; Carolyn F Deacon; Jens J Holst; Natalia Petersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.